Kailee Rainse / startuprise - UK-based Antiverse, a biotech startup developing AI-designed therapeutic antibodies for hard-to-target disease proteins, has raised $9.3 million in a Series A round led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO V…
Back to Top / Tuesday, March 3, 2026, 8:22 am / permalink 20054 / 5 stories in 3 days
Outpost Bio lands $3.5M to turn the microbiome into predictive AI infrastructure / 4 days
QT Sense raises €4M for real‐time cellular stress monitoring / 4 wks
Barcelona’s Biorce Secures Series A Funding for AI Clinical Trials Expansion / 4 wks
FluoSphera secures seed funding for 3D organ model innovation / 7 wks
Amgen acquires Oxford’s Dark Blue Therapeutics in major biotech deal / 1 month
Sweden’s Lithea secures funding for childhood cancer therapy / 4 months
Adaptam Therapeutics secures €3M for cancer immunotherapy research / 4 months
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.